Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Everolimus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    314 result(s) found for: Everolimus. Displaying page 4 of 16.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-001265-16 Sponsor Protocol Number: COEB071X2103 Start Date*: 2013-09-30
    Sponsor Name:Novartis Farma S.p.A
    Full Title: An Open-Label, Single-arm, Phase Ib/II study of AEB071 (a Protein Kinase C Inhibitor) and Everolimus (mTOR inhibitor) in Patients with CD79-mutant or ABC subtype Diffuse Large B-Cell Lymphoma
    Medical condition: Diffuse Large B-cell Lymphoma (DLBCL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022583-13 Sponsor Protocol Number: CRAD001MIC02 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, multi-center, expanded access study of RAD001 in patients with subependymal giant cell astrocytomas (SEGA) associated with tuberous sclerosis complex (TSC). The EFFECTS STUDY: Everol...
    Medical condition: The study will evaluate the safety of RAD001 in patients with subependymal giant cell astrocytomas (SEGA) associated with Tuberous Sclerosis Complex (TSC).
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) HU (Completed) CZ (Completed) FR (Ongoing) BE (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000137-39 Sponsor Protocol Number: CRAD001HFR02 Start Date*: 2012-04-06
    Sponsor Name:Novartis Pharma S.A.S
    Full Title:
    Medical condition:
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-000561-12 Sponsor Protocol Number: S.E.R.I.O. Start Date*: 2011-06-07
    Sponsor Name:ITALIAN SARCOMA GROUP
    Full Title: A phase II, open label, non-randomized study of second or third line treatment with the combination of sorafenib and everolimus in patients affected by relapsed and non-resectable high-grade ost...
    Medical condition: Patients with high-grade Osteosarcoma, not resectable/metastatic, failing at least 2 different lines of standard tr4eatment for relapsed/metastatic disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031294 Osteosarcoma metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-001290-25 Sponsor Protocol Number: CERL080A2415 Start Date*: 2005-09-14
    Sponsor Name:St Vincent's Hospital
    Full Title: A 3-Year Randomised, Open Label, Multi-Centre Investigator Driven Study Comparing de Novo Enteric Coated Mycophenolate Sodium with Delayed Onset Everolimus, Both Arms in Combination with Cyclospori...
    Medical condition: Heart-Lung, bilateral lung and single lung transplant recipients ICD Classification: K01-K01.9, E53.9+Z94.1, E53.9+Z94.2, E53.9+Z94.3
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) DE (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004383-25 Sponsor Protocol Number: CDFF332A12101 Start Date*: 2021-10-22
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A Phase I/Ib, open-label, multi-center study of DFF332 as a single agent and in combination with Everolimus or IO agents in patients with advanced/relapsed ccRCC and other malignancies with HIF2alp...
    Medical condition: Advanced, relapsed Clear Cell Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10038396 Renal carcinoma recurrent LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-006556-21 Sponsor Protocol Number: CRAD001J2301 Start Date*: 2009-09-26
    Sponsor Name:Novartis Pharma Service AG
    Full Title: Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Everolimus in Combination with Trastuzumab and Paclitaxel, as First Line Therapy in Women with HER2 Positive Locally Adva...
    Medical condition: HER2+ locally advanced or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) GB (Completed) FR (Completed) IT (Completed) IE (Completed) BE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2011-003416-23 Sponsor Protocol Number: CRAD001LDE43 Start Date*: 2012-03-12
    Sponsor Name:Novartis Pharma GmbH
    Full Title: An open label, single arm trial to evaluate patients with metastatic renal cell carcinoma treated with everolimus after failure of first line therapy with sunitinib or pazopanib
    Medical condition: metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10038409 Renal cell carcinoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004035-38 Sponsor Protocol Number: GIM16-FEVEX Start Date*: 2015-06-17
    Sponsor Name:CONSORZIO ONCOTECH
    Full Title: Fulvestrant ed EVerolimus più EXemestane nel carcinoma mammario metastatico” “Fulvestrant followed by everolimus plus exemestane vs examestane and everolimus followed by fulvestrant in postmenopaus...
    Medical condition: Hormone receptor positive (HR+) and human epidermal growth factor receptor type 2 negative (HER2-) locally advanced (LABC) or metastatic breast cancer (MBC)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000222-22 Sponsor Protocol Number: 2004/045 Start Date*: 2005-04-25
    Sponsor Name:OLV-ziekenhuis
    Full Title: Prospective Open Single-Centre Study on the Effect of Initiation of RAD and CNI minimalisation on renal function in heart transplant patients
    Medical condition: heart transplant patients with impaired renal function under treatment of CNI
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001503-38 Sponsor Protocol Number: PolEver Start Date*: 2008-06-05
    Sponsor Name:AZIENDA OSPEDALIERA PROVINCIALE DI LECCO
    Full Title: effect of everolimus on adult polycystic nephropaty; a study pilot
    Medical condition: Autosomal Dominant Plycystic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010607 Congenital renal cyst LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018792-17 Sponsor Protocol Number: KM004EIC Start Date*: 2011-07-04
    Sponsor Name:Kliniken der Stadt Koeln gGmbH, Klinikum Merheim
    Full Title: Single-center, single-armed, open-label, prospective study assessing efficacy and safety of a conversion of kidney allograft recipients suffering from Chronic Allograft Nephropathy (CAN) assessed ...
    Medical condition: This study is designed to assess whether a conversion from a CNI-based therapy to a CNI-free therapy with Certican® and Myfortic® in renal transplant patients with Chronic Allograft Nephropathy (CA...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10023438 Kidney transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000127-32 Sponsor Protocol Number: ROPETAR Start Date*: 2011-11-03
    Sponsor Name:Werkgroep Immunotherapie Nederland voor Oncologie
    Full Title: A randomized phase II study to explore the efficacy and feasibility of upfront bi-monthly rotations between Everolimus and Pazopanib with sequential treatment of first line Pazopanib and second lin...
    Medical condition: Advanced or metastatic clear cell renal cancer.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10038416 Renal clear cell carcinoma LLT
    16.1 100000004864 10009251 Clear cell carcinoma of the kidney LLT
    16.1 100000004864 10023400 Kidney cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-001680-24 Sponsor Protocol Number: ALiKE Start Date*: 2018-09-12
    Sponsor Name:Medical University of Vienna - Abteilung für Thoraxchirurgie
    Full Title: Combined low-dose everolimus and low-dose tacrolimus after alemtuzumab induction therapy: a randomized prospective trial in lung transplantation
    Medical condition: Lung Transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004831-21 Sponsor Protocol Number: SCHEDULE10years Start Date*: 2020-01-09
    Sponsor Name:Oslo University Hospital
    Full Title: 10 to 12 year extended follow-up of the SCHEDULE study (SCANDINAVIAN HEART TRANSPLANT EVEROLIMUS DE NOVO STUDY WITH EARLY CNI AVOIDANCE)
    Medical condition: Herat transplant
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10050432 Prophylaxis against heart transplant rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001897-13 Sponsor Protocol Number: ITM-LET-01 Start Date*: 2017-08-22
    Sponsor Name:ITM Solucin GmbH
    Full Title: A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to tar...
    Medical condition: Patients with inoperable, progressive, somatostatin receptor-positive(SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077559 Gastroenteropancreatic neuroendocrine tumour disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-024527-25 Sponsor Protocol Number: CRAD001H2307 Start Date*: 2013-07-23
    Sponsor Name:Novartis Farma SpA
    Full Title: A 24 month, randomized, controlled, study to evaluate the efficacy and safety of concentration-controlled everolimus plus reduced tacrolimus compared to standard tacrolimus in recipients of living ...
    Medical condition: Adults with end stage liver disease patients requiring a liver transplant.
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004865 10024716 Liver transplantation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-010196-25 Sponsor Protocol Number: CRAD001O2301 Start Date*: 2010-04-06
    Sponsor Name:Novartis Pharma Service AG
    Full Title: A randomized phase III, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of everolimus (RAD001) in adult patients with advanced Hepatocellular Carcinoma afte...
    Medical condition: hepatocellular cancer (2nd/3rd line)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) AT (Completed) ES (Completed) IT (Completed) FR (Completed) GR (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2008-008697-31 Sponsor Protocol Number: CRAD001W2301 Start Date*: 2009-11-12
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized Phase III, double-blind, placebo-controlled multicenter trial of daily everolimus in combination with trastuzumab and vinorelbine, in pretreated women with HER2/neu over-expressing loc...
    Medical condition: HER2-neu overexpressing metastatic breast cancer after previous trastuzumab use
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) GR (Completed) BE (Completed) IT (Completed) ES (Completed) FR (Completed) CZ (Completed) GB (Completed) HU (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2014-004735-39 Sponsor Protocol Number: M14NEC Start Date*: 2015-11-10
    Sponsor Name:NKI-AVL
    Full Title: Phase II Study of cisplatin and everolimus in patients with metastatic or unresectable neuroendocrine carcinomas (NEC) of extrapulmonary origin
    Medical condition: Patients with metastatic neuroendocrine carcinomas of extrapulmonary origin will be eligible
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 19:38:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA